Back to top
more

iShares Core S&P 500 ETF: (IVV)

(Real Time Quote from BATS) As of Jul 22, 2025 02:26 PM ET

$631.44 USD

631.44
1,840,525

-0.29 (-0.05%)

Volume: 1,840,525

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

1 - Strong Buy of 5 1        

Zacks News

Sanghamitra Saha headshot

A Look at Timber ETFs on Forest Day

How timber ETFs have performed of late and what lies ahead.

Sanghamitra Saha headshot

Will Semiconductor ETFs' Best Start to a Year Last Long?

Semiconductor ETFs have seen the best start to a year in 2019. Will the rally last?

Neena Mishra headshot

Forget Free, This ETF Will Pay You to Invest

This ETF will temporarily pay investors for investing in it.

Sanghamitra Saha headshot

Low-Volatility ETFs in the Pink Despite a Bull Market

Why low-volatility ETFs have gathered considerable assets and gained in prices this year while regular S&P ETFs saw asset outflows.

Sweta Killa headshot

S&P 500 Back to Above 2,800: SPY ETF Versus IVV

A low fee and dividend reinvestment option makes IVV more enticing to investors than SPY.

Neena Mishra headshot

Zero Fee ETFs: What You Need to Know

Investors are the biggest winners in fund fee wars but costs should not be the only consideration in selecting ETFs.

Sanghamitra Saha headshot

Era of Commission-Free ETFs Knocking on Investors' Door?

Forget about cut in expense ratios. Brokers are now engaged in bringing up torrents of commission-free ETFs on their trading platform.

Zacks Equity Research

Should iShares Russell Top 200 ETF (IWL) Be on Your Investing Radar?

Style Box ETF report for IWL

Sanghamitra Saha headshot

January ETF Asset Report

Inside the ETF asset generation report for the month of January.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.